31.08.2021

Neophore appoints Stephen Over as Chief Financial Officer

We are delighted to announce the appointment of Stephen Over as the Company's Chief Financial Officer and new member of the Executive team.

Stephen brings a wealth of senior leadership and strategic financing expertise with over 10 years of experience in the pharmaceuticals, biotech and medical devices industries.

See our Team

More news

11.10.2021

Additional Series B funding announcement

We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli…

22.04.2021

NeoPhore Announces Scientific Founder Dr Alberto Bardelli Awarded €2.5 million European Research Council (ERC) Advanced Grant

22 April, Cambridge, UK – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced that its scientific founder, Dr A…

09.03.2021

NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline

Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management 9 March 2021, Cambridge, UK – NeoPhore Limited, a s…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990